BamSEC and AlphaSense Join Forces
Learn More

4D Molecular Therapeutics Inc. – Material Contracts

NASDAQ: FDMT    
Share price (6/29/26): $12.88    
Market cap (6/29/26): $673 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 4 pages 4D Molecular Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program
12/34/56
EX-10.24
from 10-K 92 pages Collaboration and License Agreement
12/34/56
EX-10.23
from 10-K 10 pages Transition Agreement
12/34/56
EX-10.22
from 10-K 15 pages Background
12/34/56
EX-10.21
from 10-K 6 pages Material contract
12/34/56
EX-10.16
from 10-K 3 pages Amendment to 4D Molecular Therapeutics, Inc. 2025 Employment Inducement Award Plan
12/34/56
EX-10.2
from 10-Q 17 pages 2. Payments and Benefits
12/34/56
EX-10.1
from 10-Q 7 pages US-Docs\146996649.2 Docusign Envelope Id: E0e94006-E660-4306-A3d8-B2cd8319bf9f
12/34/56
EX-10.21
from 10-K 9 pages 4D Molecular Therapeutics, Inc. 2025 Employment Inducement Award Plan Stock Option Grant Notice
12/34/56
EX-10.20
from 10-K 6 pages 4D Molecular Therapeutics, Inc. 2025 Employment Inducement Award Plan Restricted Stock Unit Award Grant Notice
12/34/56
EX-10.19
from 10-K 22 pages 4D Molecular Therapeutics, Inc. 2025 Employment Inducement Award Plan
12/34/56
EX-10.17
from 10-K 14 pages 4D Molecular Therapeutics, Inc. Amended and Restated Change in Control and Severance Agreement
12/34/56
EX-10.16
from 10-K 15 pages Background
12/34/56
EX-10.15
from 10-K 15 pages Background
12/34/56
EX-10.14
from 10-K 5 pages Material contract
12/34/56
EX-10.1
from 10-Q 64 pages License Agreement Between 4D Molecular Therapeutics, Inc. and Astellas Gene Therapies, Inc. Dated as of July 5, 2023 License Agreement
12/34/56
EX-10.1
from 10-Q 4 pages 4D Molecular Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Program
12/34/56
EX-10.4
from 10-Q 11 pages 4D Molecular Therapeutics, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.3
from 8-K 12 pages 4D Molecular Therapeutics, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.2
from 8-K 12 pages 4D Molecular Therapeutics, Inc. Change in Control and Severance Agreement
12/34/56